Literature DB >> 15740554

Predictors of improvement in renal function after calcineurin inhibitor withdrawal for post-liver transplant renal dysfunction.

Matthew Kh Hong1, Peter W Angus, Robert M Jones, Rhys B Vaughan, Paul J Gow.   

Abstract

BACKGROUND: Renal dysfunction after liver transplantation is a major management problem. Predictors of improvement in renal dysfunction after calcineurin inhibitor therapy (CNI) withdrawal and replacement with either mycophenolate mofetil (MMF) or azathioprine (AZA) have not previously been examined.
METHODS: Retrospective analysis of 33 post-transplant patients with creatinine clearance (CrCl) below 50 mL/min who were changed from CNI to either MMF or AZA. Following CNI withdrawal patients were divided into two groups: those with improved CrCl after switching and those without, to identify the variables associated with improved renal function.
RESULTS: Variables associated with improved CrCl were: absence of hypertension or diabetes, shorter time between transplantation and switch, deterioration in CrCl in months prior to switch and treatment with MMF (compared with AZA).
CONCLUSIONS: Our findings suggest CNI withdrawal should be targeted to a subgroup of patients whose renal function is most likely to improve.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15740554     DOI: 10.1111/j.1399-0012.2004.00317.x

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  2 in total

1.  Sustained renal response to mycophenolate mofetil and CNI taper promotes survival in liver transplant patients with CNI-related renal dysfunction.

Authors:  A Kornberg; B Küpper; K Thrum; B Krause; P Büchler; J Kornberg; A Sappler; A Altendorf-Hofmann; J Wilberg; H Friess
Journal:  Dig Dis Sci       Date:  2010-09-08       Impact factor: 3.199

Review 2.  [Progress in immunosuppression].

Authors:  C P Strassburg; M J Bahr; T Becker; J Klempnauer; M P Manns
Journal:  Chirurg       Date:  2008-02       Impact factor: 0.955

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.